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Abstract 
A new class of angiogenesis inhibitors consist of a non-anticoagulating derivative of heparin, which binds to vascular endothelial cells, 
coupled to a steriod (e.g., cortisol) which suppresses ndothelial cell division. We linked heparin to a further 10 steroids in an effort to 
identify ones which would yield more effective or safer angiogenesis inhibitors. Steroids having a C3 ketone group were linked by 
reaction with a hydrazide derivative of heparin. Steroids having a C20 ketone group and lacking a C3 ketone could not be prepared by 
this method, necessitating the development of alternative methods. The most efficient was to convert he steroid into a derivative having a 
hydrazone group at C20 and then link the steroid hydrazone to heparin. Conjugates prepared from steroids having C3 ketones were at 
most 6-fold more inhibitory than the free steroids to endothelial cells in tissue culture. In contrast, steroids having a C20 ketone but 
lacking a C3 ketone (tetrahydrocortisone, tetrahydrocortisol and tetrahydro S) became highly inhibitory to endothelial cells only after 
conjugation to heparin. They inhibited [3H]thymidine incorporation by 50% at a steroid concentration f 18-30 /xM and by 95% at 300 
/xM. Since tetrahydrocortisone, tetrahydrocortisol and tetrahydro S lack glucocorticoid and mineralocorticoid activity, they may prove 
safer alternatives to cortisol for prolonged adminstration, asis likely to be necessary with anti-angiogenic therapies. 
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1. Introduction 
Angiogenesis, the development of new blood vessels, 
rarely occurs in healthy adults except during wound heal- 
ing and during phases of the female reproductive cycle 
where it is usually brief and tightly regulated [1,2]. In 
contrast, there is indefinite growth of endothelial cells 
under pathological conditions uch as diabetic retinopathy, 
rheumatoid arthritis and solid tumor growth [3-5]. Efforts 
have been made in several laboratories to exploit these 
differences by synthesizing or identifying drugs which 
Abbreviations: HAH, heparin adipic hydrazide; HAH-GA, heparin 
adipic hydrazide-glutaric cid; HH, heparin hydrazide; cortisol, hydrocor- 
tisone; EDC, 1-ethyl-3-(3-dimethylaminopropyl carbodiimide); DCC, 
N,N-dicyclohexylcarbodiimide; DMF, N,N-dimethyl formamide; PBS, 
phosphate-buffered saline; MPCE, murine pulmonary capillary endothe- 
lial; bFGF, basic fibroblast growth factor; 3LL, Lewis lung carcinoma; 
UV, Ultraviolet; TLC, thin-layer chromatography; ICs0, concentration at 
which 50% of the [3H]thymidine incorporation is inhibited. 
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inhibit angiogenesis and arrest the progression of these 
diseases [6-11]. These efforts have resulted in the develop- 
ment of AGM-1470, tissue inhibitors of metallopro- 
teinases, and suramin, which suppress the growth of solid 
tumors in rodents and are currently undergoing clinical 
trials in man [12-14]. Our approach of synthesizing hep- 
arin-steroid conjugates stemmed from the discovery by 
Foikman and his coworkers that cortisone inhibited angio- 
genesis in the chick chorioallantoic membrane assay and 
inhibited tumor growth in mice when combined with hep- 
arin as a simple mixture [15]. Structure-activity studies 
later showed that steroids uch as tetrahydro S and tetrahy- 
drocortisol, which lack glucocorticoid and mineralocorti- 
coid activity, also inhibited angiogenesis in combination 
with heparin [16]. These studies led to the description of a 
new biological activity of steroids, termed the angiostatic 
activity. 
Heparin-steroid conjugates consist of a non-anticoagu- 
lating derivative of heparin which binds to endothelial 
cells coupled to an angiostatic steroid which suppresses 
endothelial cell division. An acid-labile bond is used to 
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form the conjugate so that the steroid can be released 
within the endosomes or lysosomes of the endothelial 
cells. Although binding sites for heparin are present on 
several other cell types including hepatocytes [t7], fibrob- 
lasts [18], macrophages [19], smooth muscle cells [20] and 
neurons [21], endothelial cells are freely accessible to the 
blood and preferentially accumulate heparin upon intra- 
venous administration [22,23]. Indeed, we have found that 
a conjugate of heparin and cortisol inhibited the prolifera- 
tion of vascular endotheliial cells in vitro, retarded the 
vascularization f sponges implanted into mice, and signif- 
icantly inhibited the growth of solid Lewis lung carcino- 
mas in mice [24]. 
Long-term treatment with angiogenesis inhibitors is 
likely to be necessary in tumor therapy to suppress the 
outgrowth of dormant tumor cells. Cortisol possesses 
glucocorticoid and mineralocorticoid activities and so there 
is the possibility that prolonged therapy with cortisol con- 
jugates would cause toxic side effects associated with 
long-term corticosteroid therapy such as osteoporosis and 
cataracts [25]. 
The aim of the present: study was to identify steroids 
more suitable than cortisol for linkage to heparin and to 
develop new methods for forming heparin-steroid conju- 
gates in order to improve conjugation efficiency and maxi- 
mize antiproliferative capacity. We report here that conju- 
gates prepared with steroids lacking glucocorticoid and 
mineralocorticoid activitie:~ become inhibitory to vascular 
endothelial cells in vitro after conjugation to heparin and 
may provide more specific and safer angiogenesis in- 
hibitors. 
2. Materials and methods 
2.1. Materials 
Heparin (sodium salt; 1-I-3391; Grade 1-A from porcine 
intestinal mucosa, 180 USP units/mg) was from Sigma 
Chemicals, St. Louis, MO. Low molecular weight heparin 
was removed by concenta'ating a solution in an Amicon 
ultrafiltration cell fitted 'with a YM30 membrane until 
about 30% of the heparin appeared in the filtrate. The 
remaining higher molecular weight heparin was then used 
in the preparation of the conjugates. Steroids, 1-ethyl-3- 
(3-dimethylaminoproply c, arbodiimide) (EDC), Russell's 
viper venom (RVCL-1, freeze-dried powder reconstituted 
to 3 ml with PBS), dexl:ran (average molecular weight 
18,300 Da), Bolton-Hunter reagent (3-(p-hydroxyphenyl) 
propionic acid N-hydroxysuccinimide ester), pronase 
(Bacterial pronase E, Type XIV) and Triton X-100 were 
also from Sigma Chemicals. Adipic dihydrazide, car- 
bazole, blue tetrazolium and other chemicals were from 
Aldrich Chemical Co., Milwaukee, WI. All reagents were 
Analar or equivalent, or the best grade available. 
[3H]Thymidine (TRK 120, 25 Ci/mmol or 925 
GBq/mmol) and cartier free Na[125I] (IMS 30, 100 
mCi/ml or 3.7 GBq/ml) were from Amersham Corpora- 
tion, Arlington Heights, IL. 
Dulbecco's modified Eagle's tissue culture medium was 
obtained from Gibco BRL, Gaithersburg, MD. Endothelial 
growth medium and bovine brain extract were purchased 
from Clonetics Corp., San Diego, CA. Fetal calf serum 
was obtained from ICN Biomedicals, Costa Mesa, CA. 
Basic fibroblast growth factor (bFGF) was from R&D 
Systems, Minneapolis, MD. Ninety-six-well and 6-well 
tissue culture plates were obtained from Falcon (Becton 
Dickinson, Lincoln Park, NY). 
2.2. Preparation of heparin-steroid conjugates 
2.2.1. HAH-steroid conjugates 
HAH was conjugated to steroids having C3 ketones as 
described previously [24]. The steroids included cortisol, 
cortisone, corticosterone, deoxycorticosterone, cortex- 
olone, testosterone, progesterone and 17-a hydroxyproges- 
terone. HAH was prepared by condensing heparin with 
adipic dihydrazide in the presence of the water-soluble 
carbodiimide, EDC, at pH 4.75. The resultant HAH was 
purified by dialysis and freeze-dried. HAH was dissolved 
at 1 mg/ml in sodium acetate buffer pH 4.0. Seven 
volumes of the HAH solution were mixed with three 
volumes of a solution of each steroid in ethanol. In each 
case, the steroid was present at a 20-fold molar excess over 
hydrazide groups (assuming 10 hydrazide groups per hep- 
arin molecule). The reaction mixture was kept at room 
temperature for 16 h. The pH of the reaction mixture was 
then adjusted to 10 and dialyzed extensively against dis- 
tilled water, the pH of which had been adjusted to 10. The 
resultant HAH-steroid conjugates were freeze-dried. The 
structure of HAH-cortisol is shown in Fig. la. Other 
HAH-steroid conjugates have a similar structure, differing 
only in the steroid moiety. 
2.2.2. HH-steroid conjugates 
HH-steroid conjugates were prepared from tetrahydro- 
cortisol, tetrahydrocortisone a dtetrahydro S which lack a 
ketone at C3 but contain a ketone at C20. The conjugates 
were prepared in two steps. In the first step, a steroid 
hydrazone was prepared according to the method of Barton 
et al. [26]. Steroid was refluxed for 90 min in the presence 
of a 30-fold molar excess of hydrazine. Excess hydrazine 
was removed by rotary evaporation and the steriod hydra- 
zone was dissolved in ethanol and precipitated by the 
addition of water. 
In the second step, the carboxyl groups of accessible 
glucuronic acid and iduronic acid residues in hepafin were 
condensed with the steroid hydrazone using EDC. Heparin, 
dissolved at l0 mg/ml in distilled water, was mixed with 
an equal volume of steroid hydrazone dissolved in ethanol. 
The steroid hydrazone was in a 1.3-fold molar excess over 
carboxyl groups in the heparin molecule. A freshly pre- 
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pared solution of EDC in distilled water was added at a 
2.3-fold molar excess over carboxyl groups, and the pH of 
the solution was adjusted to 4.75 by the periodic addition 
of l M HC1. After one hour, the pH was adjusted to 10 and 
the reaction mixture was dialyzed against distilled water at 
pH 10. The conjugate was further purified by extracting it
twice with an equal volume of ethyl acetate and the 
aqueous phase was then dialyzed against distilled water at 
pH 10 and freeze-dried. The structure of HH-tetrahydro- 
cortisone is shown in Fig. lb. Conjugates prepared with 
tetrahydro S and tetrahydrocortisol had similar structures. 
2.2.3. HAH-GA-steroid conjugates 
HAH-GA-steroid conjugates were constructed with te- 
trahydro steroids in four steps. Firstly, HAH was prepared 
as described above. Secondly, the hydrazide-terminating 
residues of HAH were converted to carboxyl terminating 
residues by reaction with glutaric anhydride. Two volumes 
of a 20 mg/ml solution of HAH in 0.5 M sodium borate 
(pH 9.6) were mixed with one volume of glutaric anhy- 
dride dissolved in dioxane at 65 mg/ml. The mixture was 
allowed to react for 16 h at room temperature and then 
dialyzed against distilled water. The resultant HAH-GA 
was freeze-dried. 
In the third step, steroid hydrazone was prepared as 
described above and in the fourth step, steroid hydrazone 
was condensed with HAH-GA in the presence of EDC as 
described above for the preparation of HH-steroid conju- 
gates. After dialysis of the reaction mixture against dis- 
tilled water at pH 10, the conjugate was further purified by 
extracting it twice with an equal volume of n-butanol 
saturated with water. The aqueous phase containing the 
conjugate was further dialyzed against distilled water at 
pH 10 and freeze-dried. The structure of HAH-GA-tetrahy- 
drocortisone is shown in Fig. lc. 
2.2.4. HH-GA-steroid conjugates 
HH-GA-steroid conjugates were constructed with tetra- 
hydro steroids in three steps. In the first step, heparin 
hydrazide (HH) was prepared by condensing the accessible 
carboxylic acid residues in heparin with hydrazine. Hep- 
arin was dissolved at 10 mg/ml in 0.5 M hydrazine-HC1 at
room temperature in the presence of EDC. The pH of the 
solution was adjusted to 4.75 by the periodic addition of 1 
M HC1. When the pH had stabilized (after about 4 h) the 
mixture was left at 4°C for 72 h and then dialyzed into 1 
mM HC1 in water. The resultant HH was then dialyzed 
into distilled water and freeze-dried. 
In the second step an N-hydroxysuccinimide derivative 
of the steroid was prepared. Steroid hydrazone was pre- 
pared as described above. The steroid hydrazone was 
dissolved at 100 mg/ml in dioxane and reacted with an 
equimolar amount of glutaric anhydride at room tempera- 
ture for 2 h until the reaction was complete. The resultant 
steroid hydrazone-glutaric acid was reacted with an 
equimolar amount of N-hydroxysuccinimide in the pres- 
ence of a 1.05-fold molar excess of DCC for overnight at 
room temperature. DCC-urea was removed by filtration 
and the N-hydroxysuccinimide rivative of the steroid 
was collected in the filtrate. 
In the third step, the steroid derivative was reacted with 
HH. A 3.7-fold molar excess of steroid derivative in 
dioxane over carboxyl groups in heparin was added drop- 
wise to a 10 mg/ml solution of HH in 0.05 M sodium 
borate pH 10 with vigorous tirring. The reaction was kept 
at room temperature for 16 h and then dialyzed extensively 
against water at pH 10 and freeze-dried. The structure of 
HH-GA-tetrahydrocortisone is shown in Fig. l d. 
2.3. Analysis of heparin-steroid conjugates 
2.3.1. HAH-steroid conjugates 
The molar ratio of steroid to HAH in the conjugates 
was determined by measuring the bound steroid and HAH 
concentrations in a standard solution. Ten mg of the 
conjugate were dissolved in 1 ml of 25 mM sodium acetate 
pH 7 and dialyzed twice for two days at 4°C into 40 ml of 
25 mM sodium acetate (pH 2.1). The concentration of 
HAH retained in the dialysis bag was determined by a 
modification of the carbazole assay described by Bitter and 
Muir [27]. In brief, the HAH solutions to be analyzed were 
diluted until their approximate concentration was in the 
range of 25-250 /xg/ml. Two hundred /zl of the HAH 
solutions were added dropwise to glass tubes containing 1 
ml of an ice-cold solution of sodium tetraborate (5.03 
mg/ml) in concentrated sulfuric acid. The solutions were 
mixed and heated at 95°C for 10 min. Forty /zl of car- 
bazole (1.25 mg/ml) in absolute ethanol were added to 
each tube and the solutions were mixed and heated at 95°C 
for 15 min. The tubes were allowed to cool and the 
absorbance was measured at 530 nm. The HAH concentra- 
tions were calculated by comparing the absorbancies of 
duplicate samples of the test solutions with those of stan- 
dards prepared from HAH solutions with concentrations 
ranging from 0 to 250 /xl/ml. The molar concentration 
was calculated assuming an average molecular weight of 
16 300 Da for HAH. 
The concentration of acid-released steroid in the com- 
bined dialysates was measured spectrophotometrically. The 
extinction coefficients and "~max used were the values 
reported by the Merck Index [28] or were determined by 
scanning standard solutions of steroids. The molar ratio of 
steroid:heparin was then calculated. 
2.3.2. HH-steroid, HAH-GA-steroid and HH-GA-steroid 
conjugates 
The percentage of steroid in the conjugate was mea- 
sured spectrophotometrically t 228 nm, using an extinc- 
tion coefficient of 12400 M -1 for the semicarbazone 
derivative of the steroid in the conjugate [29] after correct- 
ing for 228 nm absorbance due to the heparin derivative. 
The molar ratio of steroid to heparin was calculated assure- 
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ing an average molecular weight of 14900 Da for HH, 
15000 Da for HH-GA, and 17700 Da for HAH-GA 
(assuming 10 carboxyl groups derivatized per heparin 
molecule in each case). 
TLC was used to confirm that the steroid which de- 
tached from the conjugate.' under acidic conditions was in 
its native form and that the amount of steroid which 
dissociated agreed with the amount determined spectropho- 
tometrically in the intact conjugate as above. A sample of 
acid-dissociated conjugate containing an expected 10 /zg 
of steroid was spotted onto a silica-coated TLC plate (60 
F254) together with standards containing 5-15 /xg of 
steroid, and ran in n-butanol saturated with water. Heparin 
derivative was visualized under UV light and native steroid 
was detected by the development of a purple spot in a 0.03 
(w/v)  blue tetrazolium solution in 1 • 1 M NaOH and 28% 
ethanol. 
2.4. Acid lability of conjugates 
A solution of conjugate (60 /zl, 1 mg/ml) in distilled 
water was added to a spectrophotometer c ll containing 
540 /zl of 0.1 M sodium acetate (pH 4.8) maintained at 
37°C. The contents of the: cell were rapidly mixed and the 
UV spectrum from 350 nm to 200 nm was scanned 
immediately and every 10 min thereafter until the decom- 
position of conjugate was complete. The half-life of the 
decomposition was taken as the time for the absorbance at
228 nm or 274 nm to decay to one-half of its initial valve 
for C20 conjugates or HAH-cortisol respectively. 
2.5. Anticoagulant activity 
The anticoagulant activity of conjugates was measured 
by the ability of the compounds to inhibit the coagulation 
of human plasma by Russell's viper venom as described 
previously [24]. Briefly, fresh citrated human plasma was 
treated with heparin or the conjugates and the time taken 
for the plasma to clot at 37°C in the presence of Russell's 
viper venom and CaC12 was recorded. The clotting times 
for the plasma treated with the conjugates were compared 
to those treated with unmodified heparin and the differ- 
ences in anticoagulating activity were calculated. 
2.6. Cell lines 
Murine pulmonary capillary endothelial (MPCE) cells 
were kindly provided by Professor Adam S.G. Curtis, 
University of Glasgow, Glasgow, UK. Human umbilical 
vein endothelial cells were purchased from Clonetics, San 
Diego, CA. C1300 murine neuroblastoma cells were kindly 
provided by Dr. Yoshikiko Watanabe, Kyoto University, 
Japan. A20 murine B-cell lymphoma cells, HS70 human 
skin fibroblasts and L6 rat skeletal muscle cells were 
purchased from the American Type Culture Collection. 
3LL murine Lewis lung carcinoma cells, Chinese hamster 
ovary cells, 3T3 murine embryo fibroblasts, Colo26 murine 
colorectal carcinoma cells and Meth-A murine sarcoma 
cells were acquired from the Imperial Cancer Research 
Fund, London, UK. 
Cells were maintained in an atmosphere of 10% CO 2 in 
air at 37°C. Human umbilical vein endothelial cells were 
cultured in endothelial growth medium containing 12 
/xg/ml bovine brain extract on gelatin-coated flasks. A20 
cells were maintained in Dulbecco's Modified Eagles 
medium supplemented with 10% (v/v)  fetal calf serum, 2 
mM L-glutamine, 2 units/ml penicillin G, and 2 /zg/ml 
streptomycin (complete medium) containing 18 mM 2- 
mercaptoethanol. The remaining cell lines were maintained 
in complete medium. 
2.7. [ 3H]Thymidine incorporation assay 
Experiments to determine inhibition of DNA synthesis 
were performed as described previously [24]. Cells were 
resuspended at (2.5- 10 4) --(2" 10 5) cells/ml, depending 
on the cell line, in the appropriate growth medium. One 
hundred /zl aliquots of cell suspension were distributed 
into the wells of 96-well tissue culture plates and incu- 
bated at 37°C for 24 h. Samples of conjugates or other 
agents were prepared in the appropriate growth medium 
and added to the wells in 100 /zl aliquots in triplicate. 
Cultures were maintained for 24 h at 37°C and then for a 
further 24 h in the presence of 1 /zCi [3H]thymidine. 
Adherent cells (MPCE, human umbilical vein endothelial 
cells, Chinese hamster ovary, 3T3, C1300, Colo26, Meth- 
A, HS70 and L6) were first detached with trypsin, and 
cells growing in suspension (A20 and 3LL) were directly 
harvested onto glass fiber disks using an automated cell 
harvester. Incorporation of [3H]thymidine was determined 
by liquid scintillation counting of the disks. 
2.8. Kinetics of DNA synthesis inhibition 
MPCE cells were resuspended at 5. l0 4 cells/ml in 
complete medium and 100 /xl aliquots of cell suspension 
were incubated for 24 h at 37°C in the wells of 96-well 
plates. One hundred/xl samples of HH-tetrahydrocortisone 
or controls were incubated with the cells for various 
periods of time at 37°C before pulsing with 2 /xCi of 
[3H]thymidine and incubating for a further hour. Cultures 
were then harvested and counted for [3H]thymidine incor- 
poration as described above. 
2.9. Preparation of [lZSI]heparin 
Heparin does not contain aromatic residues uitable for 
reaction with [1125]. Therefore, an average of one tyrosine 
residue was introduced into each heparin molecule to 
allow efficient iodination. 
Bolton-Hunter reagent was converted to a hydrazide 
derivative so that carboxyl groups in heparin could be 
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modified. A 10 mg/ml  solution of Bolton-Hunter deriva- 
tive in DMF was reacted with a 10-fold molar excess of 
hydrazine at room temperature for one hour. Excess hydra- 
zine was removed by rotary evaporation, redissolving in 
DMF and rotary evaporation to dryness. The product was 
then redissolved in DMF. A 10 mg/ml  solution of high 
molecular weight heparin in distilled water was mixed 
with the Bolton-Hunter derivative in the presence of EDC 
in the molar ratio of 1:0.65:1.3. The pH was maintained at 
4.75 for 2 h by the periodic addition of 1 M HC1. The 
mixture was then dialyzed against wo changes of distilled 
water over 24 h. Tyrosine incorporation i to heparin was 
estimated by UV spectrometry using an extinction coeffi- 
cient of 1340 M-~ in 0.1 M HC1 [30]. 
The derivatized heparin was labelled with [125I] using 
the chloramine T method according to Greenwood et al. 
[31]. The resulting [~25I]heparin had a specific activity of 
125 /~Ci per mg. 
2.10. Binding of [125I]heparin to MPCE cells 
MPCE cells were resuspended in complete medium at a 
density of 1 • 10  6 cells/ml. One ml aliquots of cell suspen- 
sion were distributed into the wells of 6-well tissue culture 
plates and incubated for 24 h at 37°C. Five hundred /xl of 
a solution of 0.08% (w/v)  sodium azide and 6.4 mg/ml  
of 2-deoxyglucose in complete medium were added to 
each culture and the cells incubated for a further 30 min at 
37°C to inhibit endocytosis. [125I]Heparin alone, or in 
combination with conjugates, heparin or dextran at differ- 
ent concentrations, was added to each culture in 500/xl of 
complete medium or to wells in which there were no cells 
growing (blanks). Plates were then incubated for 2 h at 
37°C. 
After the incubation, cultures were gently washed twice 
with 1 ml of PBS and detached and solubilized by incuba- 
tion for 30 min at 37°C with 0.5 ml of pronase (1 mg/ml)  
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Fig. 1. Structure of heparin-steroid conjugates. In a, the steroid is cortisol; in b, c, and d, the steroid is tetrahydrocortisone; 
linkage. 
* acid-sensitive acyl hydrazone 
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and 0.1% v /v  Triton X-100 in PBS. The contents of each 
well were transferred to counting tubes and the radioactiv- 
ity in each tube was measured in a gamma counter. 
Cell-associated radioactivity was determined after sub- 
straction of radioactivity associated with the plastic in the 
blank wells. The non-linear fitting program, LIGAND 
(Elsevier-BIOSOFT [32]) was used to determine the affin- 
ity of the [125I]heparin-endothelial cel interaction. 
3. Results 
Table 2 
Influence of the coupling chemistry on acid lability and anticoagulant 
activity 
Component Acid lability a Anticoagulant 
tl/2 (mins) activity (%) 
HH-steroid (C20) b 150 3.5-3.6 
HAH-GA-steroid (C20) b 30 1.0-2.2 
HAH-cortisol 15 1.1 
Heparin N/A 100 
a At 37°C in 0.1 M sodium acetate (pH 4.8) 
b Tetrahydrocortisone, tetrahydrocortisol, tetrahydro S. 
3.1. Steroid loading and purity of heparin-steroid conju- 
gates 
Steroids containing C3 ketones condensed with HAH 
under mild conditions to produce HAH-steroid conjugates 
(Fig. la). This methodology produced conjugates which 
contained 1.5 to 11.4 mol of steroid per mol of heparin 
(Table 1). Native steroid was released from the conjugates 
under acidic conditions. The released steroid had an identi- 
cal rate of movement (Rf) to standards on TLC and those 
steroids containing an alpha ketol grouping at C20 and 
C21 positions reacted with blue tetrazolium. 
Steroids containing C20 ketones and lacking C3 ketones 
(tetrahydrocortisone, t trahydrocortisol, tetrahydro S) did 
not condense with HAH under the mild conditions used to 
form the C3 conjugates. High temperatures and prolonged 
incubation conditions produced conjugates but resulted in 
modifications to the steroi~d. When the conjugates prepared 
in this way were dissociated under acidic conditions, the 
released steroids were found to be unreactive with blue 
tetrazolium and to have Rf values on TLC which were 
different from the native steroids. Three alternative meth- 
ods for coupling tetrahydro steroids were therefore de- 
vised. The first was to convert the steroid into the C20 
hydrazone derivative and then react this with native hep- 
arin to produce a heparin hydrazide-steroid conjugate 
(HH-steroid) having the structure shown in Fig. lb. The 
second was to react HAH with glutaric anhydride to 
produce the HAH-GA derivative (see Section 2) and then 
Table 1 
Influence of the coupling chemistry upon the steroid loading of heparin- 
steroid conjugates 
Conjugate Steroid loading 
% total weight mol. per mol. heparin 
HAH-steroid (C3) a 2.8-18.9 1.5-11.4 
HH-steroid (C3) b 14.4--21.0 7.5-- 10.9 
HAH-GA-steroid (C20) b 4.3--10.0 2.4--5.4 
HH-GA-steroid (C20) c 0.9 0.4 
a Cortisol, cortisone, corticosterone, deoxycorticosterone, cortexolone, 
testosterone, progesterone, 17-o: hydroxyprogesterone. 
b Tetrahydrocortisone, tetrahydtocortisol, tetrahydro S. 
c Tetrahydrocortisone. 
react this with the steroid hydrazone to produce a conju- 
gate (HAH-GA-steroid) having the structure shown in Fig. 
lc. The third was to convert the steroid into the C20 
hydrazone derivative and couple this via a glutaric acid 
spacer to HH to produce HH-GA-steroid having the struc- 
ture shown in Fig. ld. 
All three methods produced conjugates from which 
native steroid was released under acidic conditions as 
judged by movement of the released steroids on TLC and 
reaction with blue tetrazolium. HH-steroids contained up 
to 10.9 mol of steroid per mol of heparin and HAH-GA- 
steroids contained up to 5.4 mol of steroid per mol of 
heparin, in line with the steroid loading of HAH-steroid 
conjugates (Table 1). In contrast, HH-GA-steroids con- 
tained less than 1 mol of steroid per mol of heparin and 
were not further analyzed. 
3.2. Comparison of the properties of HH-steroids and 
HAH-GA-steroids prepared with tetrahydro steroids 
To determine which method of preparation of C20 
conjugates produced the most suitable conjugates for fur- 
ther study, HH-steroids and HAH-GA-steroids were com- 
pared in a number of ways with each other and with the 
heparin-steroid prototype, HAH-cortisol. 
First, the acid lability of the conjugates was compared 
(Table 2). HH-steroids broke down to give free steroid and 
HH with a half-life of 150 min at 37 ° at pH 4.8. Under the 
same conditions HAH-GA steroids broke down to give 
free steroid and HAH-GA-hydrazide with a half-life of 30 
min, indicating that the longer linker between heparin and 
the steroid allowed for faster hydrolysis of the acyl hydra- 
zone linkage. HAH-cortisol hydrolysed twice as quickly as 
HAH-GA-steroids even though the C3 conjugate contained 
a shorter linker between heparin and the steroid. This 
suggests that the C20 linkage was more stable than the C3 
linkage under acidic conditions. 
Second, the anticoagulating activity of the conjugates 
was compared (Table 2). Both C20 conjugates retained 
less than 4% of the anticoagulant activity of native hep- 
arin, i.e., less than 8 USP units/mg. This is approximately 
the same low level of anticoagulant activity as displayed 
by HAH-cortisol. 
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Fig. 2. Binding of [~2SI]heparin to MPCE cells. Cells (1 • 106 per well) 
were incubated with increasing concentrations of heparin containing 0.4 
/xCi [125I]heparin. Data from two independent experiments are shown. 
Inset shows the Scatchard plot of the experimental data. 
Third, the ability of the conjugates to bind to the 
surface of MPCE cells was compared by examining their 
ability to inhibit the binding of [125I]heparin to the surface 
of MPCE cells. [125I]Heparin bound to the surface of 
MPCE cells in a concentration-dependent manner (Fig. 2). 
Analysis of the binding data, using a non-linear fitting 
program, indicated two classes of binding sites: the first 
with a K d of 6.9 × 10 .7  M (4.7 × 10 7 sites per cell) and 
the second with a K d of 8.7 × 10 -5 M (7.8 × 108 sites 
per cell). Heparin inhibited the ability of [125I]heparin to 
bind to the surface of MPCE cells by 50% at a concentra- 
tion of 1 /xM, whereas an irrelevant polysaccharide, dex- 
tran, did not significantly inhibit [125I]heparin binding at 
30 /xM (Fig. 3). HH-steroids blocked 50% of [125I]heparin 
o 
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Fig. 3. Competition of [J25I]heparin binding to MPCE cells by heparin- 
steroid conjugates. Cells were treated with [1251]heparin (1.3.10 -6 M, 
2.5 /zCi) in combination with varying concentrations of heparin (©), 
HH-tetrahydrocortisone (• ) ,  HAH-GA-tetrahydrocortisone (O), HAH- 
cortisol ([]) or dextran (• )  for 2 h at 37°C in the presence of inhibitors 
of endocytosis. The results are expressed as the mean and standard 
deviation of triplicate determinations of [125I]heparin bound to the cells, 
as the percentage of that bound when [125I]heparin alone was incubated 
with the cells. 
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Fig. 4. Inhibition of DNA synthesis by MPCE cells by heparin-steroid 
conjugates. (a) HAH-steroids (C3-1inked); (b) HH-steroids (C20-1inked). 
Cells (seeded at 2.104 cells per well) were grown in 96-well plates for 24 
h and were then treated for 24 h at 37°C with steroids (open bars) or 
heparin-steroid conjugates (filled bars) and for a further 24 h with 
[3H]thymidine. The results are expressed as the concentration f steroid 
that inhibited [3H]thymidine incorporation by 50% relative to untreated 
controls• Bars denote the standard eviation of triplicate determinations. 
Control cultures incorporated 150000-250000 cpm. 
binding to MPCE cells at approximately the same concen- 
tration as did heparin. The slightly different shape of the 
dose response curve suggests that steroid conjugation al- 
ters the heparin structure in some way as to alter the 
binding characteristics of heparin. HAH-cortisol displayed 
a similar dose response curve to HH-steroids. HAH-GA- 
steroid inhibited the binding of [l:5I]heparin by less than 
20% at 30 /zM, with respect to heparin, suggesting that the 
presence of the long linker between heparin and the steroid 
markedly inhibited the ability of heparin in the conjugate 
to bind to the heparin receptor. HAH-GA-steroids were 
correspondingly less inhibitory than HH-steroids to vascu- 
lar endothelial cells in tissue culture (not shown). Due to 
the findings that HH-steroids were more inhibitory to 
endothelial cells and better able to bind to the heparin 
receptor than HAH-GA-steroids, the former conjugates 
were chosen for further study. 
3.3. Inhibition of DNA synthesis in MPCE cells by hep- 
arin-steroid conjugates 
The ability of the panel of heparin-steroid conjugates to 
inhibit DNA synthesis was assessed against he MPCE cell 
line using a [3H]thymidine incorporation assay. The in- 
hibitory effects were assessed in parallel with a panel of 
unconjugated steroids. Fig. 4 is a summary of the concen- 
trations of the different steroids, either free or conjugated 
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to heparin derivative, that inhibited [3H]thymidine incorpo- 
ration of MPCE cells by 50% relative to untreated con- 
trois. 
C3 conjugates comprised a group of drugs in which 
HAH was coupled to steroid through the C3 ketone. The 
most potent conjugate wa~,; that made with cortisol which 
inhibited [3H]thymidine incorporation with an IC50 of 4 
/zM with respect o steroid. Corticosterone, deoxycorticos- 
terone, progesterone and cortexolone also formed potent 
conjugates with IC50 values of 21-30 /zM. However, the 
unconjugated steroids themselves were also inhibitory to 
MPCE cells and in the raajority of cases the inhibitory 
effect of the steroid was improved by less than 2-fold after 
conjugation to HAH. 
C20 conjugates comprised a group of drugs in which 
HH was coupled to the steroid through the C20 ketone. 
Three conjugates were formed in this way, prepared from 
tetrahydrocortisone, t trahydro S and tetrahydrocortisol. 
C20 conjugates potently inhibited DNA synthesis by MPCE 
cells with IC5o values which ranged from 18-30 /~M with 
respect to steroid. In conl:rast o the majority of steroids 
containing C3 ketones, the free steroids were virtually 
inactive, having IC50 valutes greater than 300 /xM. Thus, 
the conjugates were at lea~,;t 10- to 15-fold more inhibitory 
than the unconjugated steroids. 
In each case, mixing the steroid with unconjugated 
heparin derivative did not affect the inhibitory activity of 
the steroid. Similar results to those in Fig. 4 were obtained 
in three separate xperiments. 
3.4. Specificity of  DNA synthesis inhibition by MPCE cells 
by HH-tetrahydrocortisone 
HH-tetrahydrocortisone was chosen for further study for 
three reasons. Firstly, the conjugate potently inhibited DNA 
synthesis by vascular endothelial cells in tissue culture. 
Secondly, the conjugate 'was much more inhibitory than 
the free steroid. Thirdly, letrahydrocortisone was inexpen- 
sive compared with tetrahydro S and tetrahydrocortisol. 
The inhibitory effects of HH-tetrahydrocortisone upon 
DNA synthesis of MPCE cells were assessed in paralled 
with unconjugated tetrahydrocortisone, unconjugated HH 
and a simple mixture of these two components formed by 
dissociating HH-tetrahydrocortisone i  acid (Fig. 5a). HH- 
tetrahydrocortisone inhibited [3H]thymidine incorporation 
by MPCE cells with an ICs0 of 20 /zM with respect o 
steroid and 2 /xM with respect to heparin. At a high 
concencentration f 300 /xM with respect o steroid, the 
conjugate inhibited [3H]thymidine incorporation into 
MPCE cells by greater than 95% as compared with that in 
untreated control culture.,;. In contrast, the unconjugated 
components of the conjugate were not significantly in- 
hibitory at this concentration. Similarly neither a mixture 
of HH and tetrahydrocortisone or native heparin and 
tetrahydrocortisone (in the same molar ratio as in the 
conjugate) nor a sample of conjugate which had been 
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Fig. 5. Inhibition of DNA synthesis inMPCE cells by HH-tetrahydrocor- 
tisone conjugates and lack of effects on 3LL cells. MPCE cells (seeded at 
2.104 cells per well) or 3LL cells (seeded at 2.5.103 cells per well) were 
grown in 96-well plates for 24 h and were then treated for 24 h at 37°C 
with HH-tetrahydrocortisone c jugate ([]), or with an equivalent mix- 
ture of HH and tetrahydrocortisone (O), or with tetrahydrocortisone (•),
or with HH (• )  alone. The ability of cells to incorporate [3H]thymidine 
into DNA was determined 24 h later. The results are expressed asthe 
mean and standard deviation of triplicate determinations f [3H]thymidine 
incorporation as a percentage of untreated control cultures. Control 
cultures of MPCE cells incorporated 200000 cpm and control cultures of 
3LL cells incorporated 50000 cpm. 
dissociated in acid were inhibitory to MPCE cells at 100 
/.LM, indicating that the tetrahydrocortisone had to be 
chemically joined to heparin in order to exert its inhibitory 
effect. HH-tetrahydrocortisone was also more inhibitory 
than the unconjugated components to bFGF-stimulated 
MPCE cells although the conjugate was approx. 7-fold less 
potent under these conditions (Table 3). Therefore, the 
inhibitory effects of the conjugate do not appear to be due 
to the specific counteraction of growth factor-induced an- 
giogenesis. 
In order to demonstrate that the inhibitory effects of 
HH-tetrahydrocortisone on MPCE cells were mediated 
through the binding of its heparin moiety, MPCE cells 
were incubated with HH-tetrahydrocortisone i  the pres- 
ence of an excess (100 /xM) of either heparin or the 
irrelevant control polysaccharide, dextran. The inhibitory 
activity of HH-tetrahydrocortisone was decreased l l - fold 
in the presence of free heparin but only 3-fold in the 
presence of dextran (Table 3). 
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Table 3 
Further controls demonstrating HH-tetrahydrocortisone sp cificity 
Experiment Treatment iC50 a (/zM with 
respect to steroid) 
A HH-tetrahydrocortisone 9 + 0 
Dissociated HH-tetrahydrocortisone 172 + 109 
B HH-tetrahydrocortisone 17 + 4 
Heparin + tetrahydrocortisone > 300 
C HH-tetrahydrocortisone 11 __. 5 
HH-tetrahydrocortisone + 10 ng/ml 81 + 4 
bFGF b 
HH + tetrahydrocortisone + > 300 
10 ng/ml bFGF 
D HH-tetrahydrocortisone 7 _ 4 
HH-tetrahydrocortisone + 100/zM 79 + 20 
heparin 
HH-tetrahydrocortisone + 100/xM 24+ 10 
dextran 
a The ICs0 values are taken from dose-response curves as in Fig. 5. Data 
represents mean + standard eviation of triplicate determinations. 
b 10 ng/ml bFGF increased [3H]thymidine incorporation into MPCE 
cells by 170%. 
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Fig. 6. Kinetics of DNA synthesis inhibition by HH-tetrahydrocortisone 
conjugate. MPCE cells (seeded at 2. l04 cells per well) were incubated in 
the presence of HH-tetrahydrocortisone conjugate at 100 /.LM for the 
stated times and then for a further 1 h in the presence of [3H]thymidine. 
The results are expressed as the mean and standard deviation of quad- 
ruplicate determinations of [3H]thymidine incorporation as a percentage 
of untreated control cultures. The 0 h time point represents the first 
measurement after a 1 h pulse with [3H]thymidine. Control cultures of 
MPCE cells incorporated 2800-4400 cpm. 
3.5. Effect of HH-tetrahydrocortisone onfurther cell types 
In addition to being specifically inhibitory to MPCE 
cells, HH-tetrahydrocortisone was specifically inhibitory to 
human umbilical vein endothelial cells (Table 4). In con- 
trast, HH-tetrahydrocortisone was not significantly in- 
hibitory to any of the tumor cell lines examined in this 
study. The lack of effect of HH-tetrahydrocortisone on 
3LL murine lung carcinoma cell is shown as an example in 
Fig. 5b. The conjugate was also non-inhibitory to Chinese 
hamster ovary cells and 3T3 murine fibroblasts. However, 
the inhibitory action of HH-tetrahydrocortisone was not 
specific for endothelial cells since [3H]thymidine incorpo- 
ration into human skin fibroblasts and rat skeletal muscle 
cells were also inhibited by the conjugate. 
Table 4 
Effect of HH-tetrahydrocortisone  different cell types 
Cell line 1C5o a ( p.M with 
respect to steroid) 
Human umbilical vein endothelial 28 _ 8 
Chinese hamster ovary > 300 
3T3 murine fibroblasts > 300 
HS70 human skin fibroblasts 0.8 + 0.1 
L6 rat skeletal muscle 57 + 8 
A20 murine lymphoma > 300 
C1300 murine neuroblastoma > 300 
Colo26 murine colorectal carcinoma > 300 
Meth-A murine sarcoma > 300 
3LL murine lung carcinoma > 300 
a The IC5o values are taken from dose-response curves as in Fig. 5. Data 
represents mean_ standard deviation of triplicate determinations. In all 
cases, a mixture of HH and tetrahydrocortisone displayed an IC50 value 
of greater than 30 /xm. 
3.6. Kinetics of DNA synthesis inhibition by HH-tetrahy- 
drocortisone 
The kinetics of DNA synthesis inhibition by HH-tetra- 
hydrocortisone were determined by incubating MPCE cells 
in the continuous presence of the conjugate at a concentra- 
tion of 100 /zM with respect o steroid and measuring the 
effect on [3H]thymidine incorporation with time. Fig. 6 
gives the result of a representative experiment. After an 
8-h lag phase, [3H]thymidine incorporation smoothly de- 
clined over a 72-h period. HH-tetrahydrocortisone i hib- 
ited DNA synthesis by 50% after a total of 25 h and by 
90% by 48 h. The unconjugated components of the HH- 
steroid did not significantly inhibit DNA synthesis even 
after 72 h. 
3.7. Reversibility of inhibitory effects of HH-tetrahydrocor- 
tisone on DNA synthesis by MPCE cells 
In order to determine if the inhibitory effects of HH-te- 
trahydrocortisone on DNA synthesis by MPCE cells were 
reversible, cells were either exposed to the conjugate con- 
tinuously or were washed after 24 h exposure and incu- 
bated in fresh medium. After 24 h incubation with the 
conjugate at a concentration of 300 /~M with respect o 
steroid, [3H]thymidine incorporation was inhibited by al- 
most 90% (Fig. 7). If the conjugate was allowed to remain 
in contact with the cells for a further 24 h, [3H]thymidine 
incorporation was inhibited by 99%. However, if the con- 
jugate was removed from the cells after 24 h and the cells 
then cultured for a further 24 h in fresh medium, 
[3H]thymidine incorporation levels were similar to control 
cultures which were not exposed to HH-tetrahydrocorti- 
E.J. Derbyshire t aL / Biochimica et Biophysica Acta 1310 (1996) 86-96 95 
100 
o 
._= 
.'g- 80  
.,c 
~ eo' 
g,~ 40 
0 
~ 20 
0 
0 - 
24h 48h washed 
Fig. 7. Reversible effects of HH-tetrahydrocortisone c jugate upon DNA 
synthesis. MPCE cells (seeded at 10 4 cells per well) were grown in 
96-well plates for 24 h and were then either incubated in the continuous 
presence ofHH-tetrahydrocortisone at 300 /xM for 24 or 48 h or were 
incubated with HH-tetrahydrocorlisone c jugate for 24 h then washed 
with complete medium and incubated for a further 24 h in complete 
medium lacking the conjugate. The ability of cells to incorporate 
[3H]thymidine into DNA was determined using a 4-h pulse immediately 
after each treatment. The results exe expressed asthe mean and standard 
deviation of quadruplicate d terminations f [3H]thymidine incorporation 
as a percentage of cultures incubated in the absence ofHH-tetrahydrocor- 
tisone. Control cultures of MPCE cells incorporated 20000-40000 cpm. 
sone. The reversibility of DNA synthesis inhibition by 
HH-tetrahydrocortisone i dicates that the conjugate was 
not cytotoxic to the endothelial cells over this 24-h period. 
4. Discussion 
The aim of the present study was to identify steroids 
that might be better suited than cortisol for linkage to 
heparin to provide inhibitors of angiogenesis. This was 
accomplished by screening a panel of heparin-steroid con- 
jugates for their ability to inhibit DNA synthesis by vascu- 
lar endothelial cells in tissue culture. The major findings to 
emerge from the study were (1) tetrahydrocortisone, tetra- 
hydrocortisol and tetrahydro S, which lack glucocorticoid 
and mineralocorticoid activities [33], were converted from 
non-inhibitory to inhibitory drugs by their coupling to 
heparin; (2) the method of synthesis of these conjugates 
markedly influenced their purity, yield and antiprolifera- 
tive capacity against vascular endothelial cells in tissue 
culture. 
HAH, a non-anticoagulating derivative of heparin, was 
linked to a panel of 11 different steroids. The conjugation 
of steroids containing a C3 ketone was accomplished by 
simply mixing HAH and the steroid under mildly acidic 
conditions: the hydrazide-terminating residues of HAH 
condense with the C3 ketone of the steroid to produce a 
conjugate in good yield in which the HAH and the steroid 
are linked by an acid-labile acyl hydrazone bond. Of the 
panel of 11 heparin-steroid conjugates, HAH-cortisol was 
the most potent at inhibiting the division of vascular 
endothelial cells in tissue culture. However, since cortisol 
itself was strongly inhibitory, the enhancement gained by 
linking cortisol to HAH was small, around 5-fold. This 
was true for all the HAH conjugates prepared from steroids 
having C3 ketones. 
In contrast o steroids containing a C3 ketone, steroids 
lacking a C3 ketone but containing a C20 ketone (tetrahy- 
drocortisone, tetrahydrocortisol and tetrahydro S) reacted 
slowly and insufficiently with HAH. This is because the 
C20 ketone group is relatively unreactive as compared 
with the more accessible C3 ketones [24]. Previously, we 
attempted to improve the coupling efficiency of the C20 
ketone by raising the temperature to 56°C and prolonging 
the reaction time to 14 days. This produced a conjugate 
which was apparently strongly inhibitory to MPCE cells in 
vitro [24] However, during the course of the present study 
it became clear that the steroid (tetrahydro S) which 
coupled under these conditions had undergone a rearrange- 
ment. The absorption maxima (272 nm) of the resulting 
conjugates and the properties of the acid-released steroid 
are consistent with a Mattox rearrangement of the steroid 
and the formation of an enol derivative [29,34]. The lack 
of reactivity of the steroid derivative with blue tetrazolium 
is likely to have resulted in an underestimation f steroid 
loading in the conjugates formed at 56°C and an overesti- 
mation of potency [24]. 
It was important for two reasons to find a reliable and 
efficient method for forming conjugates of tetrahydro 
steroids having only a C20 ketone group for hydrazone 
formation. Firstly, tetrahydro steroids were among those 
found by Folkrnan's group to possess the highest anglo- 
static activity in combination with heparin [16]. Secondly, 
tetrahydro steroids are metabolically inert in all but anglo- 
genesis assays and so are unlikely to cause toxic side 
effects. We therefore developed several new methods for 
synthesizing these conjugates and compared them for yield 
and activity. The optimal method was first to convert he 
steroid to the hydrazone derivative and then to condense 
the steroid hydrazone with accessible carboxyl groups on 
heparin to form HH-steroid conjugates. This methodology 
was simple, efficient and formed conjugates which had 
very low anticoagulating activity and which retained abil- 
ity to bind to heparin receptors. 
The HH-steroid conjugates prepared from tetrahydro- 
cortisone, tetrahydrocortisol and tetrahydro S were cyto- 
static to endothelial cells in tissue culture. They strongly 
inhibited DNA synthesis by endothelial cells, whereas the 
free steroids were devoid of inhibitory activity. These three 
steroids howed the greatest difference in inhibitory activ- 
ity before and after conjugation to heparin of all the 
steroids assayed. Their high inhibitory activity, when cou- 
pled to heparin, correlates with the original finding by 
Crum et al. [16], that tetrahydro steroids produce highly 
active angiogenesis nhibitors in the chick chorioallantoic 
membrane assay when mixed with heparin, and substanti- 
ates their claim that glucocorticoid or mineralocorticoid 
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activity is not required for angiostatic activity. However, in 
contrast o the original findings by Crum et al. a simple 
mixture of steroid and heparin was not inhibitory in the 
present experiments, indicating that chemical inkage of 
the components i  necessary for inhibitory effects in some 
systems but not others. 
Although further experiments are necessary to elucidate 
the mechanism by which the HH-steroids exert their in- 
hibitory effect on endothelial cells, the similarity in struc- 
ture of the three tetrahydro steroids uggests that they act 
as heparin conjugates by a common mechanism. One 
possibility is that cells have intracellular eceptors for 
tetrahydro steroids or their metabolites which mediate the 
angiostatic action of the conjugates. Specifically, we envi- 
sion that the conjugates bind to heparin receptors on the 
surface of endothelial cells, are internalized by endocytosis 
like heparin itself [19,23], and the steroid is released under 
the acidic conditions prevailing in lysosomes and endo- 
somes. It is possible that the steroid, or a metabolite 
generated by enzymes in these compartments, hen diffuses 
into the cytosol, interacts with the putative receptor, and 
acts within the nucleus on genes which directly or indi- 
rectly affect cell division. The 8-h lag phase seen before 
HH-tetrahydrocortisone begins to inhibit DNA synthesis 
by endothelial cells is consistent with a multi-step rocess. 
The inhibitory effects of HH-tetrahydrocortisone were 
not totally specifically for endothelial cells in vitro since 
the conjugate was also highly inhibitory to human skin 
fibroblasts. This is likely due to the fact that fibroblasts 
also have binding sites for heparin at their cell surface, as 
do other cell types, to which the conjugate can bind [18]. 
However, upon intravenous administration, heparin prefer- 
entially accumulates in endothelial cells [22,23] and so 
heparin-binding sites on endothelial cells may represent an 
operationally selective target for the conjugates in vivo. 
In conclusion, tetrahydrocortisone, t trahydrocortisol 
and tetrahydro S have advantages that suggest they may be 
superior to cortisol for the formation of angiogenesis n- 
hibitors by linkage to heparin. They inhibit DNA synthesis 
in endothelial cells at much lower concentrations than the 
free steroids and should prove safer than HAH-cortisol for 
prolonged administration because they lack glucocorticoid 
and mineralocorticoid activities. Experiments are now un- 
derway to compare the anti-angiogenic a tivities of HAH- 
cortisol and the new HH-tetrahydro steroid conjugates in 
vivo, and to compare their therapeutic efficacy as anti- 
tumor agents. These will be reported at a later date. 
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